Drug Safety Evaluation - WIL Research Europe 

 

WIL research Europe is based in the Netherlands and specializes in personalized contract research and expert consultancy for the non-clinical development and registration of pharmaceutical products worldwide.  Together we employ more than 1200 well trained and dedicated specialists. With laboratories in both Europe and United States we are able to provide your company the global footprint that it needs.

With a focus on regulatory preclinical development, our non-clinical support covers drug development from lead selection to marketing authorisation, from ADME, toxicology and safety pharmacology to reproduction toxicity and environmental risk assessment.

Furthermore, NOTOX experts are experienced in design and performance of dedicated development programs which are compound specific (e.g. NCE's, NBE's, vaccines and biosimilars), disease specific (e.g. anticancer), population specific (e.g. juvenile toxicity studies to support paediatric trials) and purpose specific (e.g. non-clinical support for exploratory clinical trials).

For more information please contact us directly or visit our company website:

WIL Research Europe BV
Hambakenwetering 7
5231 DD ‘s-Hertogenbosch
The Netherlands,
 
Eric van der Poll 
Contact: Eric.van.der.Poll@wilresearch.com
Phone: +31 (0)73 640 67 00

 

News
Cml europe successfully undergoes first regulatory audit for commercial product Cambridge Major Laboratories Europe (CMLE), a leading supplier of chemistry services supporting drug substance development, has successfully completed its first regulatory pre-approval inspection (PAI) for a commercial API. Read more >
Cml selected by summit corp Cambridge Major Laboratories Europe Selected to Support Summit’s “Superbug Antibiotic” Clostridium Difficle Programme Read more >
Events
Bioeurope 2011 dusseldorf Drug Development Cluster will be exhibiting at the autumn edition of BioEurope 2011 Read more >
Knowledge for growth sponsorship Drug Development Cluster sponsors the Knowledge for Growth meeting in Ghent on May 5, 2011 Read more >